- Home
- BILI vs BMRN Comparison
BILI vs BMRN Comparison
Compare BILI & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BILI
- BMRN
- Stock Information
- Founded
- BILI 2009
- BMRN 1996
- Country
- BILI China
- BMRN United States
- Employees
- BILI N/A
- BMRN N/A
- Industry
- BILI EDP Services
- BMRN Biotechnology: Pharmaceutical Preparations
- Sector
- BILI Technology
- BMRN Health Care
- Exchange
- BILI Nasdaq
- BMRN Nasdaq
- Market Cap
- BILI 11.2B
- BMRN 10.0B
- IPO Year
- BILI 2018
- BMRN 1999
- Fundamental
- Price
- BILI $30.07
- BMRN $52.36
- Analyst Decision
- BILI Buy
- BMRN Buy
- Analyst Count
- BILI 7
- BMRN 18
- Target Price
- BILI $28.00
- BMRN $91.06
- AVG Volume (30 Days)
- BILI 2.9M
- BMRN 2.8M
- Earning Date
- BILI 11-13-2025
- BMRN 10-27-2025
- Dividend Yield
- BILI N/A
- BMRN N/A
- EPS Growth
- BILI N/A
- BMRN 59.53
- EPS
- BILI 0.07
- BMRN 2.68
- Revenue
- BILI $4,101,275,719.00
- BMRN $3,094,001,000.00
- Revenue This Year
- BILI $14.54
- BMRN $13.35
- Revenue Next Year
- BILI $8.91
- BMRN $9.18
- P/E Ratio
- BILI $406.84
- BMRN $19.98
- Revenue Growth
- BILI 22.70
- BMRN 12.39
- 52 Week Low
- BILI $14.47
- BMRN $51.00
- 52 Week High
- BILI $32.50
- BMRN $73.51
- Technical
- Relative Strength Index (RSI)
- BILI 59.38
- BMRN 46.13
- Support Level
- BILI $29.75
- BMRN $51.02
- Resistance Level
- BILI $30.65
- BMRN $56.80
- Average True Range (ATR)
- BILI 0.76
- BMRN 1.81
- MACD
- BILI 0.12
- BMRN 0.02
- Stochastic Oscillator
- BILI 64.35
- BMRN 32.18
About BILI Bilibili Inc.
Bilibili is a Chinese online entertainment platform best known for its YouTube-like video-sharing site. Founded in 2009, it initially focused on long-form content centered around anime, comics, and gaming, catering primarily to Gen Z users. Over time, the platform has broadened its content offerings to include a wider range of interests, successfully attracting a more diverse audience beyond the Gen Z demographic.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.